Product Description
HuHMFG1 (AS1402) is a humanised monoclonal antibody that has undergone a phase I trial in metastatic breast cancer.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Antisoma Research
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2008-001806-17 | P2 |
Active, not recruiting |
Breast Cancer |
2010-12-17 |
2022-03-12 |
Treatments |
|
| AS1402-C-201 | P2 |
Terminated |
Breast Cancer |
2010-08-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/07/2024 |
News Article |
Antibody Drug Conjugates Market Size Potential to Reach USD 39 Billion by 2032 By IMIR Market Research Pvt. Ltd. |